Yield is still an area that requires significant improvement for many promising recombinant protein and antibody products. Especially in the field of biosimilars, the ability to manufacture products cost-efficiently has a profound competitive advantage. To facilitate high yield production, Batavia Biosciences has developed STEP®, which enables the creation of stable, mammalian CHO cell lines with at least 10-fold more bioactive biosimilar product per CHO cell compared to commercial product and state-of-the-art scientific literature. In the rapidly growing market of biosimilars STEP® technology provides a substantial competitive advantage as it allows rapid completion of preclinical phases, significant reduction in R&D costs, and very high product yield in stable pharmaceutical grade CHO producer cell lines.
Read the full article on page 10/11: